Agios Pharmaceuticals Inc (AGIO): Scott Biller , Chief Scientific Officer of Agios Pharmaceuticals Inc sold 5,000 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $50.00 per share for a total value of $250,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 31, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $37.31 per share price.On Jun 10, 2016, Scott Biller (Chief Scientific Officer) sold 27,500 shares at $65.00 per share price.Also, On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price.On Oct 30, 2015, David P Schenkein (Chief Executive Officer) sold 4,000 shares at $80.26 per share price.
Agios Pharmaceuticals Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Agios Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $47.9 and hit $50.26 on the upside , eventually ending the session at $49.83, with a gain of 4.75% or 2.26 points. The heightened volatility saw the trading volume jump to 10,99,232 shares. The 52-week high of the share price is $99.4625 and the company has a market cap of $1,896 M . The 52-week low of the share price is at $33.5.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.